Dorothy Engelking
General Counsel bei DURECT CORPORATION
Profil
Dorothy Engelking is currently the Vice President-Regulatory Affairs at DURECT Corp.
She previously worked as the Vice President-Regulatory Affairs at Actavis, Inc. from 1999 to 2006, Vice President-Global Regulatory Affairs at Kendle International LLC from 2008 to 2009, Senior Vice President-Regulatory Affairs at Xanodyne Pharmaceuticals, Inc. from 2006 to 2008, and VP-Regulatory Affairs & Quality Assurance at Adamas Pharmaceuticals LLC from 2019 to 2021.
She also held the position of Vice President-Regulatory Affairs at Neos Therapeutics, Inc. Ms. Engelking received her undergraduate and graduate degrees from South Dakota School of Mines & Technology.
Aktive Positionen von Dorothy Engelking
Unternehmen | Position | Beginn |
---|---|---|
DURECT CORPORATION | General Counsel | 01.03.2022 |
Ehemalige bekannte Positionen von Dorothy Engelking
Unternehmen | Position | Ende |
---|---|---|
ADAMAS PHARMACEUTICALS, INC. | General Counsel | 01.12.2021 |
Kendle International LLC
Kendle International LLC Miscellaneous Commercial ServicesCommercial Services Kendle International LLC provides research and development services to biopharmaceutical companies by offering value-added clinical research services and proprietary information technology. The company was founded in 1981 and is headquartered in Cincinnati, OH. | General Counsel | 01.07.2009 |
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | General Counsel | 01.07.2008 |
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | General Counsel | 01.03.2006 |
NEOS THERAPEUTICS, INC. | General Counsel | - |
Ausbildung von Dorothy Engelking
South Dakota School of Mines & Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
DURECT CORPORATION | Health Technology |
Private Unternehmen | 5 |
---|---|
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Health Technology |
Kendle International LLC
Kendle International LLC Miscellaneous Commercial ServicesCommercial Services Kendle International LLC provides research and development services to biopharmaceutical companies by offering value-added clinical research services and proprietary information technology. The company was founded in 1981 and is headquartered in Cincinnati, OH. | Commercial Services |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Health Technology |
Neos Therapeutics, Inc.
Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |